Search

Home > FierceBiotech Radio > Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place
Podcast: FierceBiotech Radio
Episode:

Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place
Category: Science & Medicine
Duration: 00:24:31
Publish Date: 2015-12-02 23:00:00
Description:

In an episode free of Valeant Pharmaceuticals and Martin Shkreli, Fierce editors discuss a Senate investigation into Gilead Sciences' pricing of the hepatitis C drug Sovaldi, BioMarin's efforts to win approval for a rare disease treatment and GlaxoSmithKline's latest woes in China.
Total Play: 0